JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB192802

Anti-VEGF Receptor 1 (phospho Y1048) 抗体

Anti-VEGF Receptor 1 (phospho Y1048) antibody

5

(1 Review)

|

(2 Publications)

Rabbit Polyclonal VEGF Receptor 1 phospho Y1048 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human FLT1 pY1048 conjugated to Keyhole Limpet Haemocyanin.

別名を表示する

FLT, FRT, VEGFR1, FLT1, Vascular endothelial growth factor receptor 1, VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor, FLT-1

1 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 1 (phospho Y1048) antibody (AB192802)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 1 (phospho Y1048) antibody (AB192802)

Immunohistochemical analysis of paraffin-embedded human brain tissue labeling VEGF Receptor 1 (phospho Y1048) with ab192802 at 1/50 (left) or ab192802 preincubated with blocking peptide (right).

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

IHC-P

applications

免疫原

Synthetic Peptide within Human FLT1 pY1048 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.

P17948

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/100", "IHCP-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Immunogen
精製に関する特記事項
ab192802 was purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 1 also known as FLT-1 is a protein that plays a critical role in the regulation of angiogenesis. Its mass is approximately 180 kDa. FLT-1 is a receptor tyrosine kinase expressed mainly on the surface of endothelial cells but also in monocytes and macrophages. The receptor binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) which initiates a series of signaling cascades important for vascular development and function.
Biological function summary

FLT-1 mediates important cellular responses such as cell migration and proliferation. Although it often functions in conjunction with other receptors like VEGFR-2 FLT-1 has unique binding affinities that modulate the availability of VEGF for other receptors. FLT-1 proteins as part of complex signaling networks actively contribute to maintaining vascular homeostasis and regulating blood vessel permeability.

Pathways

FLT-1 is an important component in the VEGF signaling pathway and also part of the PlGF/VEGF pathway. The receptor serves as a decoy to regulate the amount of VEGF interaction with VEGFR-2 influencing endothelial cell function and vascular permeability. By sequestering VEGF FLT-1 helps maintain the balance in this angiogenic signaling network interacting with proteins like VEGF PlGF and the anti-VEGF agents that target these pathways.

FLT-1 is implicated in cancer and diabetic retinopathy. Overexpression or dysregulation of FLT-1 can contribute to tumor angiogenesis which can enhance tumor growth and metastasis. In diabetic retinopathy abnormal FLT-1 activity affects retinal blood vessels leading to vision impairment. Similar interactions involve VEGFR-2 and other downstream effectors emphasizing the potential of FLT-1 as a therapeutic target for conditions associated with excessive angiogenesis and vascular dysfunction.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1 (PubMed : 16685275).. Isoform 1. Phosphorylates PLCG.. Isoform 2. May function as decoy receptor for VEGFA.. Isoform 3. May function as decoy receptor for VEGFA.. Isoform 4. May function as decoy receptor for VEGFA.. Isoform 7. Has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.
See full target information FLT1 pY1048

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Cell death & disease 16:201 PubMed40133274

2025

ATP6AP1 promotes cell proliferation and tamoxifen resistance in luminal breast cancer by inducing autophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Zhengwei Yan,Aidi Huang,Dongwen Ma,Chenao Hong,Shengmiao Zhang,Luling He,Hai Rao,Shiwen Luo

Journal of nanobiotechnology 20:7 PubMed34983556

2022

Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity.

Applications

Unspecified application

Species

Unspecified reactive species

Pegah Zanjanchi,S Mohsen Asghari,Hassan Mohabatkar,Mostafa Shourian,Mehdi Shafiee Ardestani
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com